Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.

Anaemia in myelofibrosis is a multifaceted challenge with a significant impact on patient outcomes, writes Theresa Lowry ...

For the word puzzle clue of why is the ___ blue common question from a child, the Sporcle Puzzle Library found the following ...

Compared to placebo, high-dose recombinant human erythropoietin within 2 days of life does not improve neurodevelopmental outcomes for preterm infants.

The World Anti-Doping Agency (WADA) is pleased to share positive insights from a study it recently published examining the ...

Patients carrying the SF3B1 mutation, who were positive for ring sideroblasts, or who had max baseline erythropoietin (EPO) ...

During an appearance on Patrick Bet-David's PBD Podcast in March, Sonnen boldly claimed that he and James use the same drug dealer to acquire Erythropoietin (EPO), a banned substance often employed to ...

The European Medicines Agency (EMA) has given a positive recommendation for Rytelo ( imetelstat) for the treatment of adult ...

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...

Treatment for iron deficiency anaemia includes oral iron supplements or intravenous iron. Studies have found a risk of serious allergic reactions with intravenous iron. Another option is to restore ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the Committee for Medicinal Products ...